Peritumoral expression of adipokines and fatty acids in breast cancer

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Gnerlich, Jennifer L ^a   Yao, Katharine A ^b   Fitchev, Philip S ^c   Goldschmidt, Robert A ^b   Bond, Michael C ^b   Cornwell, Mona ^c   Crawford, Susan E ^c  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^b NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPOSE TRIGLYCERIDE LIPASE; FATTY ACID; LEPTIN; OLEIC ACID; PIGMENT EPITHELIUM DERIVED FACTOR; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; EYE PROTEIN; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; PNPLA2 PROTEIN, HUMAN; SERINE PROTEINASE INHIBITOR; TUMOR MARKER;

ADULT; ARTICLE; BODY MASS; BREAST CANCER; CANCER SURGERY; CELL PROLIFERATION; CLINICAL ARTICLE; COMPARATIVE STUDY; DOWN REGULATION; FAMILY HISTORY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRADUCTAL CARCINOMA; LIPOLYSIS; LYMPH NODE METASTASIS; MASTECTOMY; MIDDLE AGED; OBESITY; PILOT STUDY; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ADIPOSE TISSUE; BREAST TUMOR; CANCER STAGING; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; LUNG CARCINOMA; METABOLISM; PAGET NIPPLE DISEASE; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR CELL CULTURE;

ADIPOKINES; ADIPOSE TISSUE; ADULT; BODY MASS INDEX; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CELL PROLIFERATION; EYE PROTEINS; FATTY ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LEPTIN; LIPASE; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; NEOPLASM STAGING; NERVE GROWTH FACTORS; OBESITY; PILOT PROJECTS; PROGNOSIS; SERPINS; SURVIVAL RATE; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84892751592     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-3274-1     Document Type: Article

References (57)

1. Kamineni A, Anderson ML, White E, et al. Body mass index, tumor characteristics, and prognosis following diagnosis of earlystage breast cancer in a mammographically screened population. Cancer Causes Control. 2013;24:305-312.
2. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol. 2002;20:1128-43.
3. Daling JR, Malone KE, Doody DR, Johnson LG, Gralow JR, Porter PL. Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer. 2001;92:720-9.
4. Ewertz M, Jensen MB, Gunnarsdottir KA, et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol. 2011;29:25-31.
5. Goodwin PJ, Boyd NF. Body size and breast cancer prognosis: a critical review of the evidence. Breast Cancer Res Treat. 1990;16:205-14.
6. Holmberg L, Lund E, Bergstrom R, Adami HO, Meirik O. Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer. 1994;30A:351-4.
7. La Vecchia C, Negri E, Franceschi S, et al. Body mass index and post-menopausal breast cancer: an age-specific analysis. Br J Cancer. 1997;75:441-4.
8. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the women's health initiative (United States). Cancer Causes Control. 2002;13: 741-51.
9. Newman SC, Lees AW, Jenkins HJ. The effect of body mass index and oestrogen receptor level on survival of breast cancer patients. Int J Epidemiol. 1997;26:484-90.
10. Reinier KS, Vacek PM, Geller BM. Risk factors for breast carcinoma in situ versus invasive breast cancer in a prospective study of pre- and post-menopausal women. Breast Cancer Res Treat. 2007;103:343-8.
11. Senie RT, Rosen PP, Rhodes P, Lesser ML, Kinne DW. Obesity at diagnosis of breast carcinoma influences duration of diseasefree survival. Ann Intern Med. 1992;116:26-32.
12. Zhang S, Folsom AR, Sellers TA, Kushi LH, Potter JD. Better breast cancer survival for postmenopausal women who are less overweight and eat less fat. The Iowa Women's Health Study. Cancer. 1995;76:275-83.
13. Stephenson GD, Rose DP. Breast cancer and obesity: an update. Nutr Cancer. 2003;45:1-16.
14. Gilbert CA, Slingerland JM. Cytokines, obesity, and cancer: new insights on mechanisms linking obesity to cancer risk and progression. Annu Rev Med. 2013;64:45-57.
15. Jeong YJ, Bong JG, Park SH, Choi JH, Oh HK. Expression of leptin, leptin receptor, adiponectin, and adiponectin receptor in ductal carcinoma in situ and invasive breast cancer. J Breast Cancer. 2011;14:96-103.
16. Vona-Davis L, Rose DP. Angiogenesis, adipokines and breast cancer. Cytokine Growth Factor Rev. 2009;20:193-201.
17. Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. Physiol Res. 2006;55:233-44.
18. Saxena NK, Taliaferro-Smith L, Knight BB, et al. Bidirectional crosstalk between leptin and insulin-like growth factor-I signaling promotes invasion and migration of breast cancer cells via transactivation of epidermal growth factor receptor. Cancer Res. 2008;68:9712-22.
19. Zimmermann R, Strauss JG, Haemmerle G, et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science. 2004;306(5700):1383-6.
20. Zechner R, Zimmermann R, Eichmann TO, et al. Fat signals- lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012;15:279-91.
21. Zhang F, Du G. Dysregulated lipid metabolism in cancer. World J Biol Chem. 2012;3:167-74.
22. Steinberg GR, Kemp BE, Watt MJ. Adipocyte triglyceride lipase expression in human obesity. Am J Physiol Endocrinol Metab. 2007;293:E958-64.
23. Langin D, Dicker A, Tavernier G, et al. Adipocyte lipases and defect of lipolysis in human obesity. Diabetes. 2005;54:3190-7.
24. Christiaens V, Lijnen HR. Angiogenesis and development of adipose tissue. Mol Cell Endocrinol. 2010;318:2-9.
25. Notari L, Baladron V, Aroca-Aguilar JD, et al. Identification of a lipase-linked cell membrane receptor for pigment epitheliumderived factor. J Biol Chem. 2006;281:38022-37.
26. Chung C, Doll JA, Gattu AK, et al. Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol. 2008;48:471-8.
27. Zhou D, Cheng SQ, Ji HF, et al. Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol. 2010;136:1719-27.
28. Jan R, Huang M, Lewis-Wambi J. Loss of pigment epitheliumderived factor: a novel mechanism for the development of endocrine resistance in breast cancer. Breast Cancer Res. 2012; 14:R146.
29. Cai J, Parr C, Watkins G, Jiang WG, Boulton M. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res. 2006;12(11 Pt 1):3510-7.
30. Fitzgerald DP, Subramanian P, Deshpande M, et al. Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage. Cancer Res. 2012;72:144-53.
31. Konson A, Pradeep S, Seger R. Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents. Cancer Res. 2010;70: 6247-57.
32. Dawson DW, Volpert OV, Gillis P, et al. Pigment epitheliumderived factor: a potent inhibitor of angiogenesis. Science. 1999;285(5425):245-8.
33. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004;89:2548-56.
34. Jarde T, Caldefie-Chezet F, Damez M, et al. Adiponectin and leptin expression in primary ductal breast cancer and in adjacent healthy epithelial and myoepithelial tissue. Histopathology. 2008; 53:484-7.
35. Guo S, Liu M, Wang G, Torroella-Kouri M, Gonzalez-Perez RR. Oncogenic role and therapeutic target of leptin signaling in breast cancer and cancer stem cells. Biochim Biophys Acta. 2012;1825:207-22.
36. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst. 2002;94:1704-11.
37. Ishikawa M, Kitayama J, Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer. Clin Cancer Res. 2004;10:4325-31.
38. Jarde T, Caldefie-Chezet F, Damez M, et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma. Oncol Rep. 2008;19:905-11.
39. Caldefie-Chezet F, Damez M, de Latour M, et al. Leptin: a proliferative factor for breast cancer? Study on human ductal carcinoma. Biochem Biophys Res Commun. 2005;334:737-41.
40. Barone I, Catalano S, Gelsomino L, et al. Leptin mediates tumor- stromal interactions that promote the invasive growth of breast cancer cells. Cancer Res. 2012;72:1416-27.
41. Gonzalez RR, Cherfils S, Escobar M, et al. Leptin signaling promotes the growth of mammary tumors and increases the expression of vascular endothelial growth factor (VEGF) and its receptor type two (VEGF-R2). J Biol Chem. 2006;281:26320-8.
42. McMurtry V, Simeone AM, Nieves-Alicea R, Tari AM. Leptin utilizes Jun N-terminal kinases to stimulate the invasion of MCF- 7 breast cancer cells. Clin Exp Metastasis. 2009;26:197-204.
43. Chen DC, Chung YF, Yeh YT, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett. 2006;237:109-14.
44. Han C, Zhang HT, Du L, et al. Serum levels of leptin, insulin, and lipids in relation to breast cancer in china. Endocrine. 2005;26: 19-24.
45. McGregor GP, Desaga JF, Ehlenz K, et al. Radiommunological measurement of leptin in plasma of obese and diabetic human subjects. Endocrinology. 1996;137:1501-4.
46. Tessitore L, Vizio B, Jenkins O, et al. Leptin expression in colorectal and breast cancer patients. Int J Mol Med. 2000;5: 421-6.
47. Wu MH, Chou YC, Chou WY, et al. Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer. 2009;100:578-82.
48. Considine RV, Sinha MK, Heiman ML, et al. Serum immunoreactive- leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996;334:292-5.
49. Sumner AE, Falkner B, Kushner H, Considine RV. Relationship of leptin concentration to gender, menopause, age, diabetes, and fat mass in African Americans. Obes Res. 1998;6:128-33.
50. Doll JA, Stellmach VM, Bouck NP, et al. Pigment epithelium- derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med. 2003;9:774-80.
51. Morris PG, Hudis CA, Giri D, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res (Phila). 2011;4:1021-9.
52. Subbaramaiah K, Howe LR, Bhardwaj P, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila). 2011;4: 329-46.
53. Borg ML, Andrews ZB, Duh EJ, Zechner R, Meikle PJ, Watt MJ. Pigment epithelium-derived factor regulates lipid metabolism via adipose triglyceride lipase. Diabetes. 2011;60:1458-66.
54. Grippo PJ, Fitchev PS, Bentrem DJ, et al. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut. 2012;61:1454-64.
55. Adjuvant! Online. Decision making tools for health care professionals. Adjuvant! for breast cancer (version 8.0). http://www. adjuvantonline.com. Accessed 14 June 2013.
56. Birch AM, Buckett LK, Turnbull AV. DGAT1 inhibitors as antiobesity and anti-diabetic agents. Curr Opin Drug Discov Dev. 2010;13:489-96.
57. Denison H, Nilsson C, Kujacic M, et al. Proof of mechanism for the DGAT1 inhibitor AZD7687: results from a first-time-inhuman single-dose study. Diabetes Obes Metab. 2013;15:136-43.